Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACCELERATE DIAGNOSTICS, INC.

(AXDX)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
0.8604 USD   -2.10%
11/17Certain Warrants of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 17-NOV-2022.
CI
11/17Certain Stock Options of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 17-NOV-2022.
CI
11/17Certain Common Stock of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 17-NOV-2022.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Business Summary
Logo Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in-vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

Number of employees : 220 people.
Sales per Business
20202021Delta
Accelerate Pheno11.0398.7%11.6398.7% +5.47%
Other0.141.3%0.151.3% +10%
USD in Million
Sales per region
20202021Delta
United States10.3192.3%10.1285.9% -1.79%
Foreign0.867.7%1.6614.1% +93.14%
USD in Million
Managers
Name Title Age Since
Jack Phillips President, Chief Executive Officer & Director 55 2020
Steven Reichling Chief Financial & Accounting Officer 42 -
Lawrence Mertz, Dr. Chief Technology Officer - 2022
Laura Pierson Investors Relation Contact - -
Cherif Amin Bousselham Senior Vice President & Head-Sales - 2018
Ron Price Chief Commercial Officer-Americas 57 2020
John Meduri Chief Strategy Officer - 2020
G. Michael Bridge Secretary, Senior Vice President & General Counsel 57 -
Kurtis Montegna Senior VP-Regulatory Affairs & Quality Assurance - 2022
Gretchen Strohminger Senior VP, Head-Human Resources & Culture - 2018
Members of the board
Name Title Age Since
John Patience Chairman 73 2012
Jack Schuler Independent Director 80 2012
Matthew William Strobeck, Dr. Independent Director 48 2012
Frank J. M. ten Brink Independent Director 64 2013
Mark Miller Independent Director 65 2013
Thomas D. Brown Independent Director 73 2017
Charles M. Watts, Dr. Independent Director 78 2017
Louise L. Francesconi Independent Director 68 -
Jack Phillips President, Chief Executive Officer & Director 55 2020
Hany Massarany Director 59 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 99,099,480 72,588,072 73.2% 0 0.0% 73.2%
Stock B 0 3,954,546 0 0.0% 0 0.0%
Shareholders
NameEquities%
Jack Schuler 18,792,022 19.0%
Griffin Asset Management, Inc. 7,302,956 7.37%
John Patience 6,810,164 6.87%
Oracle Investment Management, Inc. 2,445,791 2.47%
The Vanguard Group, Inc. 2,291,941 2.31%
Birchview Capital LP 2,252,388 2.27%
Matthew William Strobeck 2,045,560 2.06%
FIAM LLC 1,234,320 1.25%
Citadel Advisors LLC 1,187,260 1.20%
Peter B. Cannell & Co., Inc. 1,121,919 1.13%
Company contact information
Accelerate Diagnostics, Inc.
3950 South Country Club Road
Suite 470
4th floor
Tucson, AZ 85714

Phone : +1.520.365.3100
Fax : +1.520.269.6580
Web : http://acceleratediagnostics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Accelerate Diagnostics, Inc.